Approval of Olaparib Combo Impacts SOC in BRCA-Mutant Metastatic CRPC

Video

Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

In September 2022, prior to the approval of olaparib (Lynparza) plus abiraterone and prednisone, CancerNetwork® spoke with Andrew J. Armstrong, MD, MSc, regarding how the potential approval would impact the standard of care for metastatic castration-resistant prostate cancer (mCRPC) regardless of homologous recombination repair. With the current FDA approval, patients with BRCA-mutant mCRPC may now receive this treatment.1

Armstrong, professor of medicine, surgery, and pharmacology and cancer biology as well as a member of the Duke Cancer Institute at Duke University School of Medicine in Durham, North Carolina, also reviewed how this new treatment option should be considered in the first-line setting. The approval was based on data from the phase 3 PROpel trial (NCT03732820) which analyzed the combination therapy compared with matched placebo.2 

For patients with a BRCA mutation, the radiographic progression-free survival (PFS) was not reached in the olaparib arm compared with 8 months (95% CI, 6-15) in the placebo arm (hazard ratio [HR], 0.24; 95% CI, 0.12-0.45). In patients who did not have a BRCA mutation, the radiographic PFS HR was 0.77 (95% CI, 0.63-0.96).

Transcript:

For many years the standard of care for first-line therapy in men with mCRPC has been potent AR [androgen receptor] inhibitors such as abiraterone or enzalutamide [Xtandi]. These were based on major advances and delays in both radiographic progression-free survival and overall survival in this setting.

To date, until this FDA approval, we’ve not seen any combination therapies add to this standard of care. The PROpel study is the first in unselected patients to extend the amount of time that men have before their cancer progresses or they die from mCRPC in the first-line setting. It did so by demonstrating benefits above and beyond abiraterone alone—a very active comparator—by delaying this amount of time that patients have by somewhere between 8 and 10 months.

References

  1. FDA approves olaparib with abiraterone and prednisone (prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer. News release. FDA. May 31, 2023. Accessed May 31, 2023. https://bit.ly/3C2UVzg
  2. Clark NW, Armstrong AJ, Thiery-Vuilemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. N Engl J Med Evi. June 3, 2022;1(suppl 9).doi:10.1056/EVIDoa2200043

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content